This site is intended for health professionals only

Diabetes compound given Phase IIa clearance

teaser

Evolva has received regulatory clearance to progress its pharmaceutical compound EV-077 into Phase IIa clinical studies for the treatment of complications of diabetes.

The mechanism of action of EV-077 means that it can potentially ameliorate or prevent a range of diabetic complications, including loss of kidney function and increased risk of thrombosis.

Conducted in Germany on around 60 patients, the study will be a randomised, double-blind and placebo-controlled, and will investigate the efficacy and safety of EV-077 in type II diabetics with a heightened risk of diabetic vascular complications.

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

Measurements will include oxidative stress, vascular inflammation, blood flow and platelet reactivity.

Positive read-outs have previously been obtained on selected biomarkers in both healthy volunteers (in the recently completed Phase I studies) as well as in ex-vivo studies on diabetics.

“I am very pleased with the timely regulatory clearance for our next step with EV-077,” said Evolva’s Chief Medical Officer, Dr. Norbert Bender.

“We remain on track for Phase IIa data by mid-2012. We have obtained good interest from several established pharmaceutical companies in the utility of EV-077 in diabetics, and are confident that the Phase IIa data will provide a good basis for future partnering.”

Evolva






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x